Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

LCCC 2103: Development and Application of a Novel Digital Array PCR Assay for Evaluation of Minimal Residual Disease in Acute Myeloid Leukemia (AML)

NCT04920188 is registered in ClinicalTrials.gov with UNC Lineberger Comprehensive Cancer Center as lead sponsor.

NCT NCT04920188
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04920188 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
LCCC 2103: Development and Application of a Novel Digital Array PCR Assay for Evaluation of Minimal Residual Disease in Acute Myeloid Leukemia (AML)
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Phase
Observational
Overall status
Terminated
Start date
May 28, 2021
Completion date
May 25, 2024
Enrollment
10 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

leukemia, myeloid, acute, minimal residual disease